PF-Atlas › Clinical Trials › NCT05985590

A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants

BMS-986278 · Phase 1

Registry ID
NCT05985590
Phase
Phase 1
Status
Completed
Drug / intervention
BMS-986278
Sponsor
Bristol-Myers Squibb
Start
2023-08-18
Enrollment
37
Locations
1

About this trial

The purpose of the study is to assess the effects of BMS-986278 on Drospirenone (DRSP) and Ethinyl Estradiol (EE) when administered as a combined oral contraceptive in healthy female participants.

View NCT05985590 on ClinicalTrials.gov →

Explore related

Admilparant / BMS-986278 — Treatment profileAll BMS-986278 trialsAll IPF trials

Related trials

BMS-986278 — NCT05932303BMS-986278 — NCT06003426BMS-986278 — NCT06025578BMS-986278 — NCT03981094
Medical disclaimer. This page summarizes public trial data for NCT05985590 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.